Probiotics plus methotrexate in early psoriasis
Official title: Gut Microbiome Changes and Clinical Impact Induced by Treatment of Newly Diagnosed Psoriasis Patients With Probiotics and Methotrexate: a Pilot Study
Run by Alexandria University · NCT07169019 · Data updated 2026-11-12
This test will see if taking daily probiotics along with weekly methotrexate helps adults with newly diagnosed psoriasis have better skin outcomes and healthier gut bacteria than taking methotrexate alone.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Alexandria University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Alexandria) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | August 20, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | September 11, 2025 |
| Trial ID | NCT07169019 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with newly diagnosed chronic plaque psoriasis who have not used recent systemic psoriasis treatments and who can comply with daily probiotic use and follow-up visits are the intended participants.
✕Probably not a fit
People who are pregnant or breastfeeding, have contraindications to methotrexate, other active autoimmune or skin diseases, recent systemic therapy, or inability to comply with daily reporting are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with newly diagnosed chronic plaque psoriasis will receive weekly methotrexate for four months, with one group also taking a daily probiotic while the other group receives methotrexate alone. Researchers will collect PASI scores at baseline and monthly, monitor bloodwork (CBC, liver and renal function) regularly, and collect stool samples to profile the gut microbiome. The trial compares changes in disease severity and shifts in beneficial or harmful gut bacteria between the two approaches. As an early-phase pilot, it is designed to provide safety data and preliminary signals of clinical and microbiome effects rather than definitive efficacy.
Why it matters
Potential benefit: If successful, adding probiotics could reduce psoriasis severity and improve gut microbiome health during methotrexate treatment.
How similar studies have gone: Small prior studies suggest probiotics can alter the gut microbiome and may modestly improve psoriasis, but evidence remains limited and inconclusive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed patients with chronic plaque psoriasis. Exclusion Criteria: * • Psoriatic patients who used systemic treatments at least 3 months before the study, with the exception of acetritin use, in the last 3 years. * Patients who have skin infection or other skin or autoimmune diseases such as SLE, Lichen planus, Dermatomyositis and Vitiligo, by history and examination. * Pregnant or Lactating mothers. * Patients with any contraindication to methotrexate treatment. * Patients who develop any adverse reaction during systemic treatment with methotrexate that necessitates cessation of treatment before the 16th week, such as bone marrow suppression as indicated by CBC, elevated liver enzymes, or severe GIT upset. * Patients with low intellectual capacity, uneducated patients, or patients unable or unwilling to provide daily feedback about their compliance to the provided probiotics treatment.
Where it's running
-
Medical Research Institute, Alexandria University
Alexandria, Egypt Recruiting
Study contacts
- Principal investigator: Mohamed A. Alqasem, MSc — Medical Research Institute, Alexandria University
- Study coordinator: Aliaa G. Aboulela, PhD
- Email: aliaagamaleldin@alexu.edu.eg
- Phone: +201002104138
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Retinal Vessel Density and Foveal Avascular Zone Size in Psoriatic Arthritis
This study tests whether retinal blood vessel density and the size of the foveal avascular zone differ between people with psoriatic arthritis, people with psoriasis, and healthy individuals using non-invasive eye imaging.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
Can older adults with breast cancer tolerate a dense CMF chemo schedule
This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.
-
HL40626S tablets in healthy adults: a first-in-human dose study
This Phase 1 study tests HL40626S tablets in healthy adults to see if it is safe, tolerated, and how it behaves in the body after single and 14-day multiple doses.
-
Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant
This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.
-
Global psoriasis care patterns and outcomes (observational)
This study tests how psoriasis is managed across different health systems by following patients over time to see care access, treatments, disease severity, and quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.